

AUTHOR QUERY FORM

 ELSEVIER	Journal: BETH Article Number: 198	Please e-mail or fax your responses and any corrections to: E-mail: corrections.essd@elsevier.spitech.com Fax: +1 61 9699 6721
--	--	--

Dear Author,

Any queries or remarks that have arisen during the processing of your manuscript are listed below and highlighted by flags in the proof. Please check your proof carefully and mark all corrections at the appropriate place in the proof (e.g., by using on-screen annotation in the PDF file) or compile them in a separate list.

For correction or revision of any artwork, please consult <http://www.elsevier.com/artworkinstructions>.

Articles in Special Issues: Please ensure that the words ‘this issue’ are added (in the list and text) to any references to other articles in this Special Issue.

Uncited references: References that occur in the reference list but not in the text – please position each reference in the text or delete it from the list.	
Missing references: References listed below were noted in the text but are missing from the reference list – please make the list complete or remove the references from the text.	
Location in article	Query / remark Please insert your reply or correction at the corresponding line in the proof
Q1	Kindly provide the updated status of the reference.
Q2	Kindly provide the updated status of the reference.

Electronic file usage

Sometimes we are unable to process the electronic file of your article and/or artwork. If this is the case, we have proceeded by:

Scanning (parts of) your article Rekeying (parts of) your article Scanning the artwork

Thank you for your assistance.



Depression Vulnerability Moderates the Effects of Cognitive Behavior Therapy in a Randomized Controlled Trial for Smoking Cessation

Heather Schloss Kapson

David A. F. Haaga

American University

Several clinical trials have tested the hypothesis that smoking cessation treatments with a mood management component derived from cognitive behavior therapy (CBT) for depression would be specifically effective for depression-vulnerable smokers, with mixed results. This trial addressed methodological concerns with some of the previous studies to clarify whether depression vulnerability does in fact moderate CBT smoking cessation outcome. The study compared 8-session group CBT with a time-matched comparison group condition in a sample of 100 cigarette smokers randomized to treatment condition. Each treatment group was led by one of 7 American University clinical psychology graduate students; therapists were crossed with treatment conditions. Outcome (7-day point prevalence abstinence) was evaluated 1 month and 3 months after quit date. Baseline self-reported depression vulnerability (sample median split on the Depression Proneness Inventory) moderated treatment response, such that more depression-prone smokers fared better in CBT whereas less depression-prone smokers fared better in the comparison condition. These results may have implications for determining when to use CBT components in smoking cessation programs.

TOBACCO USE CONTINUES TO be the leading cause of preventable death, disability, and illness in the United States (Centers for Disease Control [CDC], 2002), yet an estimated 20% of the United States adult population are current smokers, and of these smokers 78% smoke cigarettes daily (CDC, 2008). Between 1997 and 2001, smoking-related illnesses accounted for an estimated 438,000 premature deaths per year (CDC, 2005) and, additionally, they produced about \$157 billion in annual health-related economic costs (CDC, 2002).

A commonly reported motive for cigarette smoking is negative affect (Kassel, Stroud, & Paronis, 2003). Episodic negative affect also poses a high risk of relapse for those who have recently quit smoking (e.g., Shiffman, Paty, Gnys, Kassel, & Hickcox, 1996). Finally, chronic negative affect additionally plays a significant role in smoking. For example, depressed people are overrepresented among current smokers (e.g., Acierno, Kilpatrick, Resnick, Saunders, & Best, 1996), especially smokers high in nicotine dependence (e.g., Breslau, Kilbey, & Andreski, 1991). In a longitudinal epidemiological study of young adults, those with a history of major depression at baseline were substantially more likely than those without such a history to progress to daily smoking (Breslau, Peterson, Schultz, Chilcoat, & Andreski, 1998). Moreover, depressed people appear to have a harder time quitting smoking than do nondepressed smokers (Glassman, 1993); this applies even to individuals with low, subclinical levels of depressive symptoms (Niaura et al., 2001), to populations with depressed mood (Cinciripini et al., 2003), and to those with a lifetime history of at least one period of depressed mood or anhedonia lasting at least 2 weeks (Ziedonis et al.). A recent review

This research was supported by grant 2R15CA77732-02 from the National Cancer Institute.

We are grateful to Betty Malloy and Scott Parker for statistical consultation and to Kimberly Bowen, James Douglass, Lisa Fucito, Ramaris German, Debbie Glasofer, Angela Gray, Ozge Gurel, Meaghan Leddy, Colleen Sevilla, Sarah Skopek, Melissa Tanner, and Sarah Weisberg for assistance with conducting this study.

Address correspondence to David A. F. Haaga, Ph.D., Department of Psychology, Asbury Building, American University, Washington, DC 20016-8062; e-mail: dhaaga@american.edu.

0005-7894/xx/xxx-xxx/\$1.00/0

© 2010 Association for Behavioral and Cognitive Therapies. Published by Elsevier Ltd. All rights reserved.

concluded that there may well be bidirectional linkages between smoking and depression, such that smoking can lead to depression or vice versa (Ziedonis et al., 2008).

Based on such studies linking depression and smoking, it has been hypothesized that adaptations of psychotherapies for depression could be effective in helping smokers learn alternate (nonsmoking) means of coping with negative mood states and thereby enhance the probability of successful abstinence. Given that extensive research supports the efficacy of cognitive behavior therapy (CBT; Beck, Rush, Shaw, & Emery, 1979) in the treatment of depression (e.g., Chambliss et al., 1998), several treatment programs that draw upon CBT have been applied to the smoking cessation context (Brown, 2003). CBT for smokers in general has been shown to be significantly more effective than minimal cessation advice alone through 12-month follow-up (e.g., Marks & Sykes, 2002).

Although few studies have been conducted of psychosocial treatment for smokers currently experiencing major depression (for an exception, see Hall et al., 2006), several investigators have tested the hypothesis that CBT would be specifically effective for smokers who are vulnerable to experiencing depression. The premise is that such smokers would especially benefit from learning healthier means of managing negative mood states as a way of maintaining abstinence. A history of major depression at baseline is not a significant independent predictor of failing to benefit from smoking cessation treatment (Covey, Bomback, & Yan, 2006; Hitsman, Borrelli, McChargue, Spring, & Niaura, 2003). Nevertheless, history of major depression predicts depression in the wake of smoking cessation treatment (Covey, Glassman, & Stetner, 1997), and increases in depressive symptoms in response to quitting smoking predict relapse (Burgess et al., 2002), so it is plausible that smokers vulnerable to depression could particularly benefit from mood management skills addressed in CBT.

Clinical trials testing this moderator hypothesis have yielded mixed results (Haaga, Hall, & Haas, 2006). In a sample of smokers with a history of alcohol dependence, baseline depressive symptoms interacted with treatment condition such that CBT mood management techniques were helpful only for smokers high in depressive symptoms (Patten, Drews, Myers, Martin, & Wolter, 2002). Given that baseline depressive symptom level is a significant predictor of later incidence of major depression (Lewinsohn, Solomon, Seeley, & Zeiss, 2000), this finding can be seen as consistent with the view that CBT would be especially helpful for those vulnerable to depression.

Most studies have instead operationalized vulnerability to depression as the presence of a history of major depression. Hall, Muñoz, and Reus (1994) found that a CBT group treatment added to a standard health-education-based program significantly outperformed the health education program alone only for depression-vulnerable smokers, operationalized in this study as having a history of major depression. This result was replicated by Hall et al. (1998).

However, a third clinical trial by the same research group equated the two conditions for therapy contact time and failed to replicate the interaction of depression vulnerability and treatment condition (Hall et al., 1996). In a study of smokers with a history of alcohol dependence, CBT significantly enhanced the efficacy of a behavioral treatment based on nicotine fading and self-monitoring, even with therapy contact time controlled (Patten, Martin, Myers, Calfas, & Williams, 1998). However, all participants were positive for a history of depression, so there is no way to determine whether the beneficial impact of CBT was specific to this group.

Finally, Brown and colleagues (2001) obtained a specific effect for CBT with smokers with a history of depression, but only if they had a history of recurrent depression, not just a single previous episode, suggesting that the method of measuring depression vulnerability may influence results. This effect was replicated in a secondary analysis of the three Hall et al. (1994, 1996, 1998) clinical trials cited earlier—CBT was more effective than a health education comparison condition only for participants who had experienced at least two prior major depressive episodes, not zero or one (Haas, Muñoz, Humfleet, Reus, & Hall, 2004).

The Brown et al. (2001) and Haas et al. (2004) results suggest that CBT may provide benefit specifically for depression-vulnerable smokers and that this effect might be found only at fairly high levels of depression vulnerability. These results would seem to bring welcome clarity to what has been a confusing literature, but we believe additional research is needed. History of recurrent major depression has itself proven inconsistent as a moderator of CBT effects on smoking cessation. A subsequent trial (Brown et al., 2007) did not find CBT mood management treatment (relative to standard CBT lacking the mood management component, and crossed with either bupropion or placebo) to be differentially effective among those with a history of recurrent major depression, though this nonreplication could have resulted from limited statistical power. Of the 524 patients randomized, only 16 had experienced multiple

182 prior depressive episodes. By the same token, this
 183 paucity of participants with multiple previous major
 184 depressive episodes is not just a statistical issue. It
 185 suggests that operationally defining depression
 186 vulnerability in this manner limits the vulnerable
 187 subgroup substantially in a typical smoking cessation
 188 clinic and sets constraints on the practical utility
 189 of the findings for clinicians in such settings. Most
 190 importantly, it is not clear that this substantial
 191 winnowing of the population of smokers seeking to
 192 quit actually defines the depression-vulnerable
 193 subgroup in the most valid way possible.

194 Depression history (whether recurrent or not)
 195 may be an imprecise assessment of current vulner-
 196 ability to depression for a couple of reasons (Just,
 197 Abramson, & Alloy, 2001). There might be
 198 individuals who have yet to experience a major
 199 depressive episode because no suitably major
 200 stressor has occurred, even though they are actually
 201 high in depression vulnerability. Their depression
 202 vulnerability therefore would be underestimated if
 203 assessment is based only on the past occurrence of
 204 depressive episodes. Conversely, some smokers
 205 with histories of depression might no longer be
 206 highly vulnerable to depression as a result of
 207 enduring effects of interventions used in helping
 208 them recover in the first place.

209 To address the ambiguities associated with
 210 depression history as a measure of vulnerability in
 211 the research reported in this article, we measured
 212 current depression vulnerability with the Depres-
 213 sion Proneness Inventory (DPI; Alloy, Hartlage,
 214 Metalsky, & Abramson, 1987). To our knowledge,
 215 only two previous studies of cognitive-behavioral
 216 interventions for cigarette smokers have used the
 217 DPI as a predictor. A comparison of CBT with an
 218 intervention based upon motivational interviewing
 219 found no specific benefit of CBT for depression-
 220 vulnerable (high-DPI) smokers (Smith et al., 2001).
 221 However, this study differed from earlier CBT
 222 studies in that CBT and motivational interviewing
 223 were implemented as “step-up” treatments after an
 224 initial brief intervention and cessation attempt. It is
 225 not known whether results would be similar were
 226 these treatments implemented from the outset of the
 227 smoking cessation attempt. Conversely, Brandon
 228 et al. (1997) did report a selective effect of CBT for
 229 those high in depression proneness.

230 In view of the Brown et al. (2001) and Haas et al.
 231 (2004) findings indicating that a high level of
 232 depression vulnerability is necessary to show a
 233 selective benefit of CBT for smoking cessation, we
 234 did not predict that the DPI as a continuous variable
 235 in a sample unselected for depression vulnerability
 236 would moderate treatment response. Instead, we
 237 expected that high levels of depression vulnerability

would be necessary. Taxometric research conducted
 238 in a large sample of treatment-seeking smokers
 239 suggested that the DPI validly measures a taxonic
 240 construct of depression proneness (Strong, Brown,
 241 Kahler, Lloyd-Richardson, & Niaura, 2004). In the
 242 absence of precise guidance from the literature on
 243 what DPI score would be high enough to suggest
 244 probable membership in the “depression-prone”
 245 taxon,¹ we used our sample median split to select
 246 high and low depression-prone groups.
 247

In summary, several studies have obtained
 248 interactive effects such that CBT mood manage-
 249 ment therapy is specifically effective for depression-
 250 vulnerable smokers, but findings have been incon-
 251 sistent, perhaps as a function of methods of
 252 measuring depression vulnerability. We therefore
 253 conducted a randomized clinical trial of CBT and a
 254 time-matched comparison treatment. We hypothe-
 255 sized that self-rated current depression proneness
 256 would interact with type of treatment in predicting
 257 abstinence outcomes through 3 months after quit
 258 date. CBT was expected to be more effective than
 259 the comparison condition for those above the
 260 sample median in depression proneness, but not
 261 for those below the median.
 262

Method

PARTICIPANTS

Cigarette smokers were recruited from the
 265 Washington, DC, metropolitan area via newspaper
 266 advertisements, community fliers, public service
 267 announcements, advocacy organizations (e.g.,
 268 American Lung Association), online postings (e.g.,
 269 www.craigslist.org), and community and university
 270 health centers and hospitals. Advertisements soli-
 271 cited “smokers who want to quit” and indicated
 272 that help would be provided in the form of “group
 273 therapy sessions” or “group counseling”; there was
 274 no mention of mood management, cognitive
 275 behavior therapy, or depression proneness in the
 276

¹ Strong et al. (2004) obtained an estimated base rate of 19% for the depression-prone taxon, which would imply that our characterization of those participants above the DPI sample median as highly depression-prone is overly liberal. However, (a) their taxometric analyses were based on a subset of DPI items, so it is not possible to reconstruct an exact total DPI score optimally separating the taxon members from nonmembers; (b) there was variability in the base rates estimated from different taxometric analyses, suggesting that more research is needed to pin this figure down more precisely; and (c) most importantly, their sample appears to have been less depression-prone than ours. Their sample obtained total DPI scores averaging 23.18 ($SD = 8.12$), whereas ours obtained a mean of 31.71 ($SD = 11.32$). As such, our above-the-median subsample (32 and higher) were all at least one standard deviation above the mean of the Strong et al. sample and therefore likely candidates for the depression-prone taxon even with only 19% of their sample qualifying as such.

ads. Cigarette smokers were enrolled in the program if they smoked at least 1 cigarette per day for the past 4 weeks, wanted to quit smoking, were fluent in English, were willing to be treated in a group setting, and were at least 18 years old. We set a low minimum smoking rate for eligibility (relative to some other trials that require, for instance, ≥ 10 cigarettes/day) because even very light smoking (1 to 4 cigarettes/day) has been linked in longitudinal epidemiological research with death from heart disease and with all-cause mortality (Bjartveit & Tverdal, 2005). As such, practice guidelines (USDHHS, 2008) recommend helping all tobacco users to quit.

Prospective participants were excluded and referred elsewhere if they were actively suicidal, on the premise that smoking cessation can be stressful and could exacerbate suicidal ideation.

One hundred participants (49 male, 51 female) both enrolled in the program and were randomized to a treatment condition. Four participants enrolled in the program but dropped out prior to randomization; therefore, these participants were excluded from all remaining analyses. The sample size was determined by the number of eligible participants we were able to enroll and treat within the project funding period. The moderator effect of depression vulnerability in CBT smoking cessation studies has been erratic (see Introduction), and we did not have a confident *a priori* estimate of its effect size for sample size planning purposes. There were no interim analyses conducted during the study. Figure 1 summarizes the flow of participants from assessment to follow-up and analysis.

Participants ranged in age from 20 to 68 years ($M=42.85$, $SD=12.80$) and reported 9 to 21 years of education ($M=15.84$, $SD=2.46$). Participants were full-time employed (56%), part-time employed (14%), had a leave of absence or were unemployed (11%), were full-time students (8%), or retired (7%). Their annual household incomes ranged from less than \$10,000 to over \$200,000 with the most common range (17%) being between \$50,000 to \$75,000.

A majority of participants were Caucasian (65%), whereas about one-quarter were African American (29%), with the remaining participants being Asian American (2%) or other races (3%). About one-tenth of the participants (9%) were of Hispanic ethnicity.

Pretreatment daily smoking rates varied widely, from 4 to 60 cigarettes, with an average just under a pack a day ($M=17.76$, $SD=8.34$). All participants reported having smoked for at least 1 year (mean years smoked = 23.49, $SD=13.33$). Participants estimated that they tried to quit up to 50 times

before (median = 3; 25th percentile = 1; 75th percentile = 5). Their longest previous quit attempts ranged from less than 1 day to 6,120 days (median = 90; 25th percentile = 21; 75th percentile = 270). The participants reported moderate nicotine dependence on the Fagerström Test for Nicotine Dependence ($M=4.66$, $SD=2.34$).

MEASURES

Suicidality was assessed with the Beck Scale for Suicide Ideation (BSI; Beck, Steer, & Ranieri, 1988). The interviewer determined if significant suicidal ideation was present by following up on any positive responses on this questionnaire. If so, the participant was excluded from the study and referred elsewhere so that suicidal ideation could be addressed first.

Sample demographics and smoking history were assessed using brief, face valid questionnaires concerning age, gender, socioeconomic status, number of cigarettes smoked per day, number of past quit attempts, age at which the first cigarette was smoked, and the number of years that the participant smoked daily.

Nicotine dependence was measured with the Fagerström Test for Nicotine Dependence (FTND; Heatherton, Kozlowski, Frecker, & Fagerstrom, 1991). This 6-item self-report has moderate internal consistency ($\alpha=.64$), satisfactory retest reliability over 2 to 3 weeks ($r=.88$), and positive correlations with cotinine levels ($r=.39$), with self-reports of "addiction" as a reason to smoke ($r=.53$), and with the number of years as a smoker ($r=.52$; Pomerleau, Carton, Lutzke, Flessland, & Pomerleau, 1994). Depression proneness was measured with the Depression Proneness Inventory (DPI; Alloy et al., 1987). The DPI is a 10-item self-report measure of vulnerability to depressive reactions to stress. The DPI is face valid, as the questions ask about proneness to depression (e.g., "Would your friends who know you best rate you as a person who easily becomes very depressed, sad, blue, or down in the dumps?"). Each item is rated on a 1 to 7 Likert-type scale, and the total DPI score is the sum of the item scores (i.e., 10 to 70). The DPI is highly internally consistent ($\alpha=.90$ in nonclinical samples) and stable (1-month retest reliability $r=.88$; Alloy et al.). The DPI has correlated positively with current depressive symptoms and with number of past episodes of major or minor depressive disorder, but not with past episodes of anxiety disorders, mania, or drug and alcohol abuse (Alloy et al., 1987), supporting its specificity to depression proneness. A prospective study in an undergraduate sample supported its predictive validity in that DPI scores




FIGURE I The CONSORT E-Flowchart.

from the beginning of an introductory psychology course predicted increased depressive symptoms in the wake of a poor performance on a midterm examination above and beyond what could be predicted on the basis of Time 1 depression scores (Alloy et al.). In a clinical trial of smoking cessation methods, smokers who lapsed even once during the first week after a quit attempt had scored higher on the DPI at baseline than did those who maintained abstinence during the first week (Smith et al., 2001). In descriptive studies of smokers, DPI scores have been positively correlated with interview-

derived diagnoses of past major depression (Haaga et al., 2004) and with self-reported motivation to smoke in order to reduce negative mood (Brody et al., 2005). The association of DPI scores with past major depression was significant even after controlling for age, gender, and current depressive symptoms (Strong et al., 2004).

Smoking status was measured by self-report. When participants self-reported abstinence, expired air carbon monoxide (CO) was measured for verification purposes. Self-reports were collected in person at each treatment session after quit date

(sessions 5 through 8), at a posttreatment assessment 1 month after quit date, and by phone at 3 months after quit date. CO measurement always took place in person. If a participant reported abstinence by phone at the 3-month follow-up, an appointment was made for the participant to have their CO level measured in person. Our outcome measure was 7-day point prevalence abstinence, which entailed self-report of no use of tobacco products in the prior 7 days, as well as an expired air carbon monoxide (CO) reading of ≤ 8 parts per million (SRNT Subcommittee on Biochemical Verification, 2002). Seven-day point prevalence abstinence is the metric used in compiling results for the U.S. Department of Health and Human Services practice guideline (USDHHS, 2008). At each follow-up (1 month and 3 months post target quit date) there was one participant whose self-reported abstinence was disconfirmed by the CO reading, resulting in reclassification as a smoker.

Therapist adherence was measured by audiotaping each group treatment session. Masked raters who were familiar with the manuals developed for each condition subsequently rated a random sample of session tapes with respect to which therapy condition was being conducted, as a measure of the differentiability of the treatment conditions. Independently, additional raters aware of what condition was being conducted and of the session number rated a random sample of session tapes with regard to whether each of the topics or activities highlighted in the manual was actually addressed in the session.

PROCEDURE

Design Overview, Research Setting, and Therapists We randomized participants to one of two types of group smoking cessation treatment: (a) comparison condition: scheduled reduced smoking plus health education and (b) CBT condition: scheduled reduced smoking plus health education plus cognitive behavior therapy mood management procedures. Each condition consisted of eight sessions of 90 minutes each. Treatment length was held constant so that any differences in outcome between the two conditions could not be attributed to extra treatment time (Haaga & Stiles, 2000). Each group consisted of approximately three to five participants with one of the seven graduate student therapists trained and then supervised weekly throughout the study. The supervisor (David Haaga, Ph.D.) is a licensed clinical psychologist with extensive training and experience in CBT and in training and supervising student therapists using these same treatments in a pilot study for this project (Thorndike, Friedman-Wheeler, & Haaga, 2006). To avoid confounding general therapist skill

with treatment condition, therapists were crossed with condition. All assessments were conducted in the Department of Psychology at American University. Treatment group sessions were held in the psychotherapy training clinic housed within the same department.

Assessment Sequence

Smokers who called in response to study advertisements were screened over the phone. Those appearing likely to be eligible were scheduled for an in-person pretreatment assessment. Upon completion of the 8-session intervention, each participant was asked to complete an individual posttreatment assessment session approximately 1 week after the treatment's conclusion (1 month after quit date) as well as a 3-month posttreatment follow-up appointment.

Pretreatment assessment. All assessments were conducted individually. Along with an appointment reminder letter, participants received a self-monitoring form that requested the participant to monitor baseline levels of daily smoking and time spent asleep (information required for planning the details of scheduled reduced smoking). At the beginning of the pretreatment assessment, a trained master's or doctoral student completed written informed consent with the participant. The study was conducted in accordance with APA ethical standards and was approved by the American University IRB.

Participants were asked then to complete the Beck Suicidality Index (BSI). If any ideation was endorsed, the study staff conducted a clinical interview, provided hotline and referral information, and discussed the clinical management of the participant with the principal investigator. If the risk of suicide was none to minimal, the assessment session proceeded.

Participants were asked to provide a \$40.00 deposit at the pretreatment assessment; \$20 was returned upon completion of the posttreatment assessment, and the remaining \$20 was returned upon the completion of the 3-month follow-up assessment.

In addition to smoking history, nicotine dependence, demographic, and depression vulnerability measures (as described in the Measures subsection), participants completed several questionnaires and computerized behavioral assessment tasks not relevant to this report (Schloss & Haaga, in press).

After individual pretreatment assessments were conducted with enough eligible participants to form a new group, and the group had been scheduled with a therapist, the project director would so

inform the principal investigator. The PI then used a random number table to assign the group to a treatment condition (CBT or comparison) and informed the project director and therapist of this assignment. No subject variables were used to stratify random assignment. During pretreatment assessment, therefore, both assessors and participants were masked to treatment condition. During posttreatment and follow-up assessments such masking was not possible, but both participants and assessors remained masked to pretreatment depression proneness scores throughout the study, and smoking status reports were subject to biochemical corroboration and therefore should not be biased by knowledge of the treatment condition assignment.

Posttreatment assessment. Approximately 1 week after completion of the final treatment session for both the comparison and CBT conditions (i.e., 1 month after quit date), participants were scheduled for an individual posttreatment assessment session. Similar to the pretreatment assessment, participants were interviewed about their smoking status and then completed the same measures provided at the pretreatment assessment (excluding demographics and smoking history).

Three-month follow-up. Three months after the scheduled quit date, the study staff called group participants to inquire about their smoking status. If a participant indicated that she or he was abstinent, then that participant was scheduled to visit American University to have this report corroborated by an expired CO reading.

555 TREATMENTS

556 *Treatment: Common Components*

557 Each condition was guided by a treatment manual
558 (available from the corresponding author) and
559 incorporated an education component, as well as
560 scheduled reduced smoking with a target quit date
561 for all participants between the fourth and fifth
562 therapy sessions. In each condition, all sessions
563 were audiotaped for use in evaluating therapist
564 adherence (see Results section).

566 *Education*

567 The psychoeducation component addressed nico-
568 tine dependence and withdrawal symptoms. Partici-
569 pants were encouraged to analyze how the
570 negative consequences of smoking (e.g., health
571 risks, financial costs) applied to them in particular,
572 along with what benefits they might obtain from
573 smoking cessation. In the first session, participants'
574 smoking histories were discussed, along with any

previous quit attempts and where they might have
575 gone awry. The education component also empha-
576 sized the value of physical exercise, social support
577 for nonsmoking, and self-reinforcement. Practical
578 strategies for handling common temptation situa-
579 tions were discussed in each group, including very
580 concrete strategies for the target quit date such as
581 discarding all tobacco products from one's home
582 and reminding one's friends and family of the
583 participant's commitment to nonsmoking. Each
584 group addressed concerns about weight gain
585 following cessation, identifying for instance low-
586 calorie snacks that could be used when a participant
587 wants something in her or his mouth instead of a
588 cigarette and exercise plans feasible for each
589 participant's lifestyle and current fitness. Finally,
590 each condition included the option of using nicotine
591 replacement, and participants in all groups received
592 information about the nicotine patch. Nicotine
593 replacement was monitored by therapists but was
594 neither provided nor required as part of the study
595 treatment. As part of the consent process, partici-
596 pants had agreed not to participate in any other
597 form of counseling for smoking cessation during the
598 study, but nicotine replacement or medication
599 treatment was allowed.

602 *Scheduled Reduced Smoking*

Participants in each treatment condition prepared
603 for quit date using scheduled reduced smoking
604 (Cinciripini, Wetter, & McClure, 1997). This
605 method directs smokers to smoke only at designated
606 times, on a predetermined schedule. The schedule
607 gradually increases the amount of time between
608 cigarettes and reduces the number of cigarettes
609 smoked daily. In principle, adherence to such a
610 schedule should make cessation easier because (a)
611 gradual reduction of nicotine leads to diminished
612 withdrawal symptoms after quit date, and (b)
613 smoking at predetermined times should help break
614 associations between the act of smoking and specific
615 environmental or internal cues. Protocol instruc-
616 tions for this component of treatment were adapted
617 from a manual by Cinciripini, Baile, and Blalock
618 (undated). Previous research showed increased
619 year abstinence in a CBT smoking cessation
620 program among those who had been assigned to
621 scheduled reduced smoking prior to quit date,
622 compared to scheduled, nonreduced smoking,
623 nonscheduled/nonreduced smoking (i.e., abrupt
624 cessation), or nonscheduled reduced smoking (i.e.,
625 number fading; Cinciripini et al., 1995).

627 *CBT Condition: The Unique Component*

The CBT mood management component of the
629 program was based on Muñoz, Organista, and Hall
630

(1993), a manual tested in Hall et al. (1994) and Hall et al. (1996), as well as a protocol for "negative affect reduction counseling" by Brandon and colleagues (Herzog et al., 2002). Participants in CBT groups were taught to identify and evaluate negative cognitions and their impact on mood. They were asked to keep a record of their negative automatic thoughts and to evaluate the evidence bearing on these thoughts. Therapists taught participants to identify more adaptive, alternative thoughts when minimal evidence for the automatic thought existed. Participants were encouraged to intervene and cope with negative thoughts through cognitive restructuring instead of smoking. Toward the end of treatment, participants discussed with the help of the other group members how they would cope with their individual high-risk situations in the future (similar plans were made in the comparison condition, but not in relation to the use of mood management techniques).

Data Analysis

The hypothesized interaction of Treatment Condition X Depression Proneness was tested using both 1-month and 3-month point prevalence abstinence data within the Generalized Estimating Equations (GEE) framework, as recommended by Hall et al. (2001). GEE was implemented using SPSS 17.0, with robust covariance estimator, the Logit link function, and unstructured correlation matrix specified. The within-subject effect was time (1 month and 3 months after target quit date), and the dependent variable was abstinence. Predictor variables in the model were depression proneness (DPI sample median split: ≥ 32 vs. ≤ 31), treatment condition (CBT vs. comparison condition), and the interaction of depression proneness and treatment condition.

Results

BASELINE COMPARISONS

Demographics, depression proneness, and cigarette smoking variables from the pretreatment assessment are reported separately by treatment condition in Table 1. Our sample scored about one-third to one-half a standard deviation higher in depression proneness than a sample of smokers not seeking treatment ($M=26.00$, $SD=9.69$; Haaga et al., 2004) and a large adult sample consisting of a mix of current smokers, former smokers, and never-smokers ($M=28.56$, $SD=11.50$; Brody, Hamer, & Haaga, 2005). Demographics and smoking variables from pretreatment are reported separately by level of depression proneness in Table 2. Differences were nonsignificant, with two

exceptions. First, the highly depression prone were more likely to be Caucasian, and the less depression prone were more likely to be African American.² Second, as might be expected, the highly depression prone were more likely to have ever taken antidepressant medication. However, it should be noted that they did not exceed their low-depression-proneness counterparts in taking anti-depressant medication as part of the current smoking cessation attempt, which was uncommon in our sample (6% of the high-DPI subsample, 10% of the low-DPI subsample).

PARTICIPANT FLOW AND ATTENDANCE AT ASSESSMENT AND THERAPY SESSIONS

Enrollment of participants in the study occurred from January 2005 through January 2007. Seventy-one percent of participants completed the 1-month post-quit-date assessment, and 82% completed the 3-month assessment. Eighty-five percent of the participants provided at least some follow-up data on smoking status.

Participants on average attended a little over one half of the 8 scheduled sessions. Comparison condition participants ($M=4.60$, $SD=2.81$) did not differ significantly from CBT participants ($M=4.35$, $SD=2.86$) in session attendance, $t(98)=0.43$, $p>.6$. About one eighth (12%) of participants refused treatment altogether, attending zero sessions. In some cases, these were people who had been kept waiting for a group to form, and by the time it started they had quit smoking, sought help elsewhere, or had their schedules change in such a way that they could not attend. With treatment refusals excluded, average attendance still did not differ significantly between the Comparison condition ($M=4.98$, $SD=2.57$) and CBT condition ($M=5.23$, $SD=2.27$), $t(86)=0.47$, $p>.6$.

IMPLEMENTATION OF INTERVENTIONS

All treatment sessions were audiotaped to facilitate clinical supervision as well as to assess the differentiability of the interventions and therapist adherence to the manualized interventions. With respect to differentiability, 15% of the session

² Despite this baseline difference in race as a function of depression proneness, race was not included as a covariate in our main analyses because (a) it was not prespecified as a covariate to include in planning the clinical trial, and adjusting for unplanned covariates because of baseline differences between groups may bias estimates of treatment effects (Altman, 1998; Raab, Day, & Sales, 2000); and (b) it was not predictive of outcome (focusing only on African Americans and Caucasians, the subgroups for whom we had enough participants to conduct an analysis, there was no significant relation between race and 3-month point prevalence abstinence, $X^2 (1) = 1.16$, $p = .28$.

t1.1 Table 1

t1.2 Pretreatment Characteristics of Comparison Condition and CBT Participants

t1.3		Comparison (n=52)	CBT (n=48)
Demographics			
t1.5	Mean (SD) Years of Age	42.73 (12.88)	42.98 (12.85)
t1.6	% female	48	54
t1.7	Race: % Caucasian	60	71
t1.8	% African American or Black	32	25
t1.9	% Asian American	2	2
t1.10	% other or declined to answer	6	2
t1.11	Ethnicity: % Hispanic	12	6
t1.12	Employment: % employed fulltime	52	60
Smoking: Current			
t1.14	Mean (SD) cigarettes per day	17.48 (9.88)	18.06 (6.35)
t1.15	Nicotine dependence (FTND Mean (SD))	4.67 (2.38)	4.65 (2.32)
Smoking and Quitting History			
t1.17	Mean (SD) years of smoking	23.09 (13.21)	23.92 (13.58)
t1.18	Median (25%ile, 75%ile) prior quit attempts	3 (1.5, 5)	2 (1, 5)
t1.19	Median (25%ile, 75%ile) days longest prior quit	60 (18, 240)	105 (21, 292)
t1.20	Depression Proneness: Mean (SD) DPI total	31.54 (11.98)	31.90 (10.71)
t1.21	Ever Taken Antidepressant medication (%)	50	48

t1.22 Note. CBT=Cognitive Behavior Therapy; FTND=Fagerstrom Test for Nicotine Dependence; DPI=Depression Proneness Inventory.

728 audiotapes were selected at random for evaluation
 729 by one of two graduate student raters. The raters
 730 were familiar with the treatment manuals but were
 731 masked to what condition was intended for each
 732 session tape. They correctly identified the session as
 733 either CBT or comparison 100% of the time (30 of
 734 30 tapes).

735 A separate random sample of tapes (32 sessions)
 736 was selected for use in rating therapist adherence by
 737 one of two graduate student raters. For this task,
 738 the raters were made aware of the treatment

739 condition and session number and were familiar 739
 740 with the manuals. They completed a checklist of the 740
 741 topics to be addressed in each session (typically 6 or 741
 742 7 per session). Raters indicated that 100% of the 742
 743 intended topics were covered in the comparison 743
 744 condition sessions (and no CBT mood management 744
 745 content was detected in these sessions), with 99% of 745
 746 the intended topics covered in CBT sessions. All 746
 747 told, it appeared that raters could tell the conditions 747
 748 apart, and therapists were implementing essentially 748
 749 all of the methods called for by the protocol. 749

t2.1 Table 2

t2.2 Pretreatment Characteristics of High- and Low-Depression Prone Participants

t2.3		Low DPI (n=48)	High DPI (n=50)	t (96) (χ^2) [U]	p
Demographics					
t2.5	Mean (SD) Years of Age	43.48 (12.60)	41.82 (13.00)	0.64	.52
t2.6	% female	54	48	0.37	.54
t2.7	Race: % Caucasian	54	76	(5.91)	.02
t2.8	% African American	40	18		
t2.9	% Asian American	0	4		
t2.10	% other	6	2		
t2.11	Ethnicity: % Hispanic	6	12	(0.97)	.32
t2.12	Employment: % employed fulltime	56	54	(0.05)	.82
Smoking: Current					
t2.14	Mean (SD) cigarettes per day	17.77 (6.07)	17.80 (10.23)	0.02	.99
t2.15	Nicotine dependence (FTND Mean (SD))	4.67 (2.14)	4.62 (2.56)	0.10	.92
Smoking and Quitting History					
t2.17	Mean (SD) years of smoking	24.80 (13.19)	22.12 (13.57)	0.99	.32
t2.18	Median (25%ile, 75%ile) prior quit attempts	2 (1, 5)	3 (2, 5)	[883.5]	.13
t2.19	Median (25%ile, 75%ile) days longest prior quit	30 (21, 210)	112 (30, 364)	[811.5]	.16
t2.20	Ever taken antidepressant medication (%)	35	62	(6.92)	.008

t2.21 Note. FTND=Fagerstrom Test for Nicotine Dependence; Low DPI=Depression Proneness Inventory ≤ 31 at pretreatment; High DPI=Depression Proneness Inventory ≥ 32 at pretreatment; U=Mann-Whitney U test statistic.

750 ADVERSE EVENTS

751 The Beck Depression Inventory (BDI) was administered at each assessment and treatment session with
 752 the aim of tracking any increases in depressive
 753 symptoms during treatment. An increase (at any
 754 point) of 8 points or more on the BDI relative to the
 755 pretreatment assessment was flagged as an adverse
 756 event. This value falls within the range (e.g., 6.64 in
 757 McGlinchey, Atkins, & Jacobson, 2002; 11 in
 758 Persons, Bostrom, & Bertagnolli, 1999) of estimates
 759 of the magnitude of BDI change signifying statistically
 760 reliable deterioration. By this definition, nine partic-
 761 ipants in CBT and five in the comparison condition
 762 experienced increased depressive symptoms, which
 763 was not a significant difference across conditions, X^2
 764 ($df=1$, $N=100$) = 1.05, $p=.30$. Also, one participant
 765 in each condition experienced an increase from
 766 pretreatment to posttreatment in daily smoking rate.
 767

768 MODERATOR EFFECT OF DEPRESSION PRONENESS
 769 ON EFFICACY OF CBT

770 To test the hypothesized interaction of depression
 771 proneness and treatment condition, we conducted a
 772 GEE analysis as described in the Method section. The
 773 main effect of treatment condition was not signifi-
 774 cant, Wald chi-square ($df=1$) = 0.82, $p>.3$. Likewise,
 775 the main effect of depression proneness was not
 776 significant, Wald chi-square ($df=1$) = 0.45, $p>.5$.
 777 However, the interaction of treatment condition and
 778 depression proneness was a significant predictor of
 779 abstinence, Wald chi-square ($df=1$) = 4.04, $p<.05$,
 780 $B=-2.01$ (95% confidence interval = -3.97 to -.05).

781 The interaction effect was in the predicted
 782 direction. To illustrate it, Table 3 and Figure 2
 783 show the 7-day point prevalence abstinence rates at
 784 each follow-up. For example, at 3 months post-quit
 785 date, among those high in baseline depression
 786 proneness abstinence rates were higher in CBT
 787 (35% to 22%), whereas among those low in




FIGURE 2 Seven-Day Point Prevalence Abstinence Percentages in Each Treatment Condition for High and Low Depression-Prone Smokers at Each Follow-up. Note. CBT = Cognitive Behavior Therapy; High DPI = Depression Proneness Inventory ≥ 32 ; Low DPI = Depression Proneness Inventory ≤ 31 .

depression proneness abstinence rates were higher 788 in the comparison condition (33% to 10%). 789

790 SECONDARY ANALYSES OF PROCESS VARIABLES
 791 Collapsing across treatment condition, we exam- 792 ined in exploratory analyses a couple of potential 793 process predictors of 3-month abstinence. 794

795 Session Attendance

In the pilot study for this project, we had found that 795 participants who attended every treatment session 796 were significantly more likely to become abstainers 797 than were those who did not. This relation held in 798 the current study as well. Of the 16 participants 799 attending all 8 treatment sessions and providing 3- 800 month follow-up data, 50% ($n=8$) were 3-month 801 abstainers, compared to 18% (12 of 66) of those 802 who missed at least one session, chi-squared ($df=1$, 803 $N=82$) = 7.07, $p<.01$, phi = .29, OR = 4.5 (95% 804 CI = 1.41 to 14.39). This correlational finding does 805 not establish a causal effect of session attendance. It 806 could instead stem from reverse causality (e.g., those 807 who are getting more out of treatment are poten- 808 tially more likely to keep attending) or the effect of a 809

t3.1 Table 3
 Seven-Day Point Prevalence Abstinence Percentages in Each
 Treatment Condition for High and Low Depression-Prone
 Smokers at Each Follow-up

		CBT	Comparison	OR
<i>One Month After Quit Date</i>				
Depression Proneness	High	41	29	1.68
	Low	16	50	0.19
<i>Three Months After Quit Date</i>				
Depression Proneness	High	35	22	1.94
	Low	10	33	0.31

Note. CBT = Cognitive Behavior Therapy; OR = odds ratio for efficacy of CBT within each level of depression proneness (High = Depression Proneness Inventory ≥ 32 ; Low = Depression Proneness Inventory ≤ 31).

third variable (e.g., high motivation to quit smoking could lead to both perfect session attendance and successful abstinence).

Adjunctive Use of Nicotine Replacement

About one-third of participants (34%) reported at any point having used nicotine replacement products. There was no difference between treatment conditions, X^2 ($df=1$, $N=96$) = 0.63, $p>.4$, or between groups defined by median split on the DPI, X^2 ($df=1$, $N=94$) = 0.05, $p>.8$, in the frequency of using nicotine replacement. Approximately one-third (10 of 31, 32%) of participants who used nicotine replacement were abstinent at the 3-month follow-up, a proportion that did not differ significantly from the abstinence rate (10 of 50, 20%) among those who chose not to use nicotine replacement, X^2 ($df=1$, $N=80$) = 1.55, $p>.2$.

Discussion

In a randomized controlled trial of small-group smoking cessation interventions, self-rated depression proneness moderated response to CBT. In particular, abstinence was more likely among the highly depression-prone if they were assigned to a treatment condition incorporating the use of cognitive restructuring as a mood management method, whereas less depression-prone smokers fared better if assigned to a time-matched comparison condition omitting the cognitive restructuring component and mood management emphasis. Both conditions involved scheduled reduced smoking prior to quit date, health education, an emphasis on social support seeking inside and outside the group, planning for challenges in the early days after quitting, and other standard psychosocial methods.

It seems likely that CBT mood management treatment helps depression-vulnerable smokers by giving them other means, aside from smoking, to respond to the negative mood states that they often experience and that prompt relapse for some recent quitters. An issue for future empirical research is to pin down the nature of this mediating mechanism of the effects of CBT for depression-vulnerable smokers. Descriptive research has implicated poor coping skills as a correlate of depression vulnerability among smokers (Haaga et al., 2004; Kahler, Brown, Lloyd-Richardson, & Niaura, 2003; Rabois & Haaga, 1997), but to date there is no evidence that CBT has a specific effect in improving these coping skills (Thorndike et al., 2006). This possibility, and other candidate mechanisms, should be evaluated in samples large enough to support powerful analyses of mediation effects for treatments exerting specific benefits only for a

subgroup (e.g., the more depression-prone) of participants, in other words “mediated moderation” (Muller, Judd, & Yzerbyt, 2005).

Conversely, for less depression-vulnerable smokers, inclusion of mood management techniques derived from CBT for depression might be something of a waste of time, addressing a concern that does not really apply to them. In this regard, it is important to note that the treatment conditions in this study were time-matched, so it is possible that the common components (health education, social support, weight management, self-reinforcement, etc.) could have received shorter shrift in the CBT condition, to the detriment of the low-depression-vulnerable smokers. No topics or techniques were eliminated altogether from the CBT condition, but a given topic (e.g., brainstorming strategies for rewarding oneself for achieving abstinence goals) might have been addressed at greater length in groups in the comparison condition given that they did not need to incorporate cognitive restructuring practice/instruction in sessions. This concern is particularly salient in our study given that (a) participants who began treatment averaged approximately 5 sessions attended, and (b) perfect attendance (8 of 8 sessions) was associated with better outcomes. Thus, it is possible that more treatment time is better and that the treatment dose for many of our participants was not high, so any time spent on a skill or topic a given participant does not need (e.g., mood management for those not prone to depression) is potentially problematic.

This issue poses a methodological challenge for any study employing a dismantling design to try to isolate the impact of a subset of treatment techniques. If treatment time is held constant, as in this study and in, for one example, a well-known dismantling investigation of cognitive therapy of depression (Jacobson et al., 1996), then the common treatment component(s) may be weaker in the experimental condition(s) incorporating extra components. On the other hand, if that problem is prevented by letting the combination treatment run longer, as in Hall et al. (1994), then additional treatment time per se becomes a viable rival hypothesis for the effects of the isolated treatment component.

Our findings are consistent with several previous demonstrations of an interaction of depression vulnerability with treatment condition in the study of CBT for smokers (e.g., Brandon et al., 1997; Brown et al., 2001; Haas et al., 2004; Hall et al., 1994; Hall et al., 1998; Patten et al., 2002) but are inconsistent with other reports of failures to replicate the effect (e.g., Brown et al., 2007; Hall et al., 1996). As described in the Introduction, we

believe that measurement issues may be relevant in determining these inconsistencies and believe that our reliance on self-reported current depression proneness rather than history of depression is a methodological strength of this study. Future research could evaluate the role of measurement method more definitively either by (a) quantitatively reviewing the full set of studies of depression vulnerability as a moderator of CBT effects for smokers and determining whether effects are significantly heterogeneous and, if so, whether partitioning the studies by type of depression vulnerability measure reduces that heterogeneity, or (b) conducting a large prospective study incorporating multiple measures of depression vulnerability. A prospective-study methodology for resolving measurement issues in this area would have the advantage of determining whether our results are replicable and whether the DPI score (≥ 32) range selected in our sample on the basis of a median split is optimal as a marker of high vulnerability.

METHODOLOGICAL ISSUES

The results reported in this manuscript should be interpreted in light of the strengths and limitations of the study. On the positive side, participants were randomly assigned to conditions, and self-reported abstinence was corroborated by expired air CO levels. Treatment conditions were differentiable by coders unaware of the intended condition, and therapist adherence ratings were high.

Methodological limitations include a modest sample size for studying moderator effects, making replication especially important. Interactions between patient variables and treatment conditions are potentially important both theoretically and practically (e.g., Latimer, Katulak, Mowad, & Salovey, 2005) but are often small effects and therefore somewhat erratic in individual studies (Noar, Benac, & Harris, 2007). Also, while differentiability of treatments was assured, and therapist adherence measured, there was no measure of therapist competence, leaving open the question of whether the CBT and comparison conditions were equally well executed.

Finally, the follow-up duration of 3 months after quit date was relatively brief. Longer term follow-ups may well have yielded lower 7-day point prevalence abstinence rates. For example, in both CBT conditions (one combined with bupropion, the other with placebo) in Brown et al. (2007), abstinence rates at 12 months were 18%. At the 2-month follow-up, the CBT abstinence rates were 25% and 26%, quite similar to the rate in this study at 3 months (see Table 3). Although a longer

duration of follow-up would likely have lowered our absolute abstinence rates, we do not have a conceptual basis for predicting that longer follow-up would have eliminated the moderator effect we observed.

Conclusion

Thus, numerous questions remain for future research, such as the mediating mechanisms for, and durability at longer follow-ups of, the moderator effect of depression vulnerability on the efficacy of CBT for smokers. However, if future studies corroborate our findings, the results have straightforward clinical implications.

Most importantly, practitioners may be able to enhance smoking cessation outcomes by measuring depression proneness at baseline and incorporating CBT mood management interventions *only* for the highly depression-vulnerable. If our findings prove replicable, the practical effects of such a strategy would be important. Considering 3-month point prevalence data (Table 3), a clinician matching interventions to depression proneness (CBT for highly depression-prone, comparison for low depression-prone) could anticipate success with 34% of smokers, whereas a mismatching strategy would yield 16% successes, and a random strategy (use CBT or comparison without regard to depression proneness) 25% successes. Deliberate mismatching is unlikely as a real-world scenario, but matching relative to random allocation would result in important gains given the large population of smokers. The number-needed-to-treat for this difference (34% vs. 25%) is 11, meaning that for every 11 smokers treated, there would be one additional favorable result (abstinence in this case).

Also, clinicians could highlight for cigarette smokers that, while causal inferences are not warranted on the basis of our correlational findings, high engagement in the treatment (operationalized in our study as perfect attendance at 8 sessions of treatment) is at least associated with a substantially greater likelihood of successful abstinence.

References

- Acierno, R. A., Kilpatrick, D. G., Resnick, H. S., Saunders, B. E., & Best, C. L. (1996). Violent assault, posttraumatic stress disorder, and depression: Risk factors for cigarette use among adult women. *Behavior Modification*, 20, 363–384.
- Alloy, L. B., Hartlage, S., Metalsky, G. I., & Abramson, L. Y. (1987). *The Depression Proneness Inventory: A brief, face-valid scale of vulnerability to depressive reactions in response to stress*. Unpublished manuscript, Temple University Philadelphia, PA.
- Altman, D. G. (1998). Adjustment for covariate imbalance. In P. Armitage & T. Colton (Eds.), *Encyclopedia of biostatistics* (pp. 1000–1005). New York: John Wiley & Sons.

- 1031 Beck, A. T., Rush, A. J., Shaw, B. F., & Emery, G. (1979).
 1032 *Cognitive therapy of depression*. New York: Guilford Press.
- 1033 Beck, A., Steer, R., & Ranieri, W. (1988). Scale for suicide
 1034 ideation: Psychometric properties of a self-report version.
 1035 *Journal of Clinical Psychology*, 44, 499–505.
- 1036 Bjartveit, K., & Tverdal, A. (2005). Health consequences of
 1037 smoking 1–4 cigarettes per day. *Tobacco Control*, 14,
 1038 315–320.
- 1039 Brandon, T. H., Juliano, L. M., Copeland, A. L., Collins, B. N.,
 1040 Quinn, E. P., & Lazev, A. B. (1997, April). *Matching
 1041 smokers to treatment based on negative affectivity*. Paper
 1042 presented at the annual meeting of the Society of Behavioral
 1043 Medicine. San Francisco, CA.
- 1044 Breslau, N., Kilbey, M., & Andreski, P. (1991). Nicotine
 1045 dependence, major depression, and anxiety in young adults.
 1046 *Archives of General Psychiatry*, 48, 1069–1074.
- 1047 Breslau, N., Peterson, E., Schultz, L., Chilcoat, H., & Andreski,
 1048 P. (1998). Major depression and stages of smoking: A
 1049 longitudinal investigation. *Archives of General Psychiatry*,
 1050 55, 161–166.
- 1051 Brody, C. L., Hamer, D. H., & Haaga, D. A. F. (2005).
 1052 Depression vulnerability, cigarette smoking, and the
 1053 serotonin transporter gene. *Addictive Behaviors*, 30,
 1054 557–566.
- 1055 Brown, R. A. (2003). Comorbidity treatment: Skills training for
 1056 coping with depression and negative moods. In D. B.
 1057 Abrams, R. Niaura, R. A. Brown, K. M. Emmons, M. G.
 1058 Goldstein, & P. M. Monti (Eds.), *The tobacco dependence
 1059 treatment handbook: A guide to best practices*
 1060 (pp. 178–229). New York: Guilford Press.
- 1061 Brown, R., Kahler, C., Niaura, R., Abrams, D., Sales, S.,
 1062 Ramsey, S., Goldstein, M., Burgess, E., & Miller, I. (2001).
 1063 Cognitive-behavioral treatment for depression in smoking
 1064 cessation. *Journal of Consulting and Clinical Psychology*,
 1065 69, 471–480.
- 1066 Brown, R. A., Niaura, R., Lloyd-Richardson, E. E., Strong,
 1067 D. R., Kahler, C. W., Abrantes, A. M., Abrams, D., &
 1068 Miller, I. W. (2007). Bupropion and cognitive-behavioral
 1069 treatment for depression in smoking cessation. *Nicotine
 1070 & Tobacco Research*, 7, 721–730.
- 1071 Burgess, E. S., Kahler, C. W., Niaura, R., Abrams, D. B.,
 1072 Goldstein, M. G., & Miller, I. W. (2002). Patterns of change
 1073 in depressive symptoms during smoking cessation: Who's at
 1074 risk for relapse? *Journal of Consulting and Clinical
 1075 Psychology*, 70, 356–361.
- 1076 Centers for Disease Control and Prevention. (2002). Annual
 1077 smoking-attributable mortality, years of potential life lost,
 1078 and economic costs—United States, 1995–1999. *Morbidity
 1079 and Mortality Weekly Report*, 51, 300–303.
- 1080 Centers for Disease Control and Prevention. (2005). Annual
 1081 smoking-attributable mortality, years of potential life lost,
 1082 and economic costs—United States, 1997–2001. *Morbidity
 1083 and Mortality Weekly Report*, 54, 625–628.
- 1084 Centers for Disease Control and Prevention. (2008). Cigarette
 1085 smoking among adults—United States, 2007. *Morbidity and
 1086 Mortality Weekly Report*, 57, 1221–1226.
- 1087 Chambliss, D. L., Baker, M. J., Baucom, D. H., Beutler, L. E.,
 1088 Calhoun, K. S., Crits-Christoph, P., Daiuto, A., DeRubeis,
 1089 R., Detweiler, J., Haaga, D. A. F., Johnson, S. B., McCurry,
 1090 S., Mueser, K. T., Pope, K. S., Sanderson, W. C., Shoham,
 1091 V., Stickle, T., Williams, D. A., & Woody, S. R. (1998).
 1092 Update on empirically validated therapies, II. *The Clinical
 1093 Psychologist*, 51, 3–16.
- 1094 Cinciripini, P. M., Baile, W. F., & Blalock, J. (undated). *Project
 1095 CASSI: Smoking cessation study*. University of Texas M. D.
 1096 Anderson Cancer Center. Department of Behavioral Science.
 1097 Tobacco Research & Treatment Program.
- 1098 Cinciripini, P. M., Lapitsky, L., Seay, S., Wallfisch, A., 1099
 1099 Kitchens, K., & Vunakis, H. V. (1995). The effects of 1100
 1100 smoking schedules on cessation outcome: Can we improve 1101
 1101 on common methods of gradual and abrupt nicotine 1102
 1102 withdrawal? *Journal of Consulting and Clinical Psychology*, 1103
 1103 63, 388–399.
- 1104 Cinciripini, P. M., Wetter, D. W., Fouladi, R. T., Blalock, J. A., 1105
 1105 Carter, B. L., Cinciripini, L. G., & Baile, W. F. (2003). The 1106
 1106 effects of depressed mood on smoking cessation: Mediation 1107
 1107 by postcessation self-efficacy. *Journal of Consulting and
 1108 Clinical Psychology*, 71, 292–301.
- 1109 Cinciripini, P. M., Wetter, D. W., & McClure, J. B. (1997). 1110
 1110 Scheduled reduced smoking: Effects on smoking abstinence 1111
 1111 and potential mechanisms of action. *Addictive Behaviors*, 1112
 1112 19, 13–22.
- 1113 Covey, L. S., Bomback, A., & Yan, G. W. Y. (2006). History of 1114
 1114 depression and smoking cessation: A rejoinder. *Nicotine &
 1115 Tobacco Research*, 8, 315–319.
- 1116 Covey, L. S., Glassman, A. H., & Stetner, F. (1997). Major 1117
 1117 depression following smoking cessation. *American Journal
 1118 of Psychiatry*, 154, 263–265.
- 1119 Glassman, A. (1993). Cigarette smoking: Implications for 1119
 1120 psychiatric illness. *American Journal of Psychiatry*, 150, 1120
 1121 546–553.
- 1122 Haaga, D. A. F., Hall, S. M., & Haas, A. (2006). Participant 1123
 1123 factors in treating substance use disorders. In L. G. 1124
 1124 Castonguay & L. E. Beutler (Eds.), *Principles of 1124
 1125 therapeutic change that work* (pp. 275–292). Oxford: 1125
 1126 Oxford University Press.
- 1127 Haaga, D. A. F., & Stiles, W. B. (2000). Randomized clinical 1128
 1128 trials in psychotherapy research: Methodology, design, and 1129
 1129 evaluation. In C. R. Snyder & R. E. Ingram (Eds.), 1130
*Handbook of psychological change: Psychotherapy pro- 1130
 1131 cesses and practices for the 21st century* (pp. 14–39). New 1131
 1132 York: Wiley.
- 1133 Haaga, D. A. F., Thorndike, F. P., Friedman-Wheeler, D. G., 1133
 1134 Pearlman, M. Y., & Wernicke, R. A. (2004). Cognitive 1134
 1135 coping skills and depression vulnerability among cigarette 1135
 1136 smokers. *Addictive Behaviors*, 29, 1109–1122.
- 1137 Haas, A. L., Muñoz, R. F., Humfleet, G. L., Reus, V. I., & Hall, 1137
 1138 S. M. (2004). Influences of mood, depression history, and 1138
 1139 treatment modality on outcomes in smoking cessation. 1139
Journal of Consulting and Clinical Psychology, 72, 563–570.
- 1140 Hall, S. M., Delucchi, K. L., Velicer, W. F., Kahler, C. W., 1141
 1141 Ranger-Moore, J., Hedeker, D., Tsoh, J. Y., & Niaura, R. 1142
 1142 (2001). Statistical analysis of randomized trials in tobacco 1143
 1143 treatment: Longitudinal designs with dichotomous outcome. 1144
Nicotine & Tobacco Research, 3, 193–202.
- 1145 Hall, S., Muñoz, R., & Reus, V. (1994). Cognitive-behavioral 1146
 1146 intervention increases abstinence rates for depressive-history 1147
 1147 smokers. *Journal of Consulting and Clinical Psychology*, 62, 1148
 1148 141–146.
- 1149 Hall, S., Muñoz, R., Reus, V., Sees, K., Duncan, C., Humfleet, 1150
 1150 G., & Hartz, D. (1996). Mood management and nicotine 1151
 1152 gum in smoking treatment: A therapeutic contact and 1152
 1153 placebo-controlled study. *Journal of Consulting and Clinical
 1153 Psychology*, 64, 1003–1009.
- 1154 Hall, S., Reus, V., Muñoz, R., Sees, K., Humfleet, G., Hartz, D., 1155
 1155 Frederick, S., & Triffleman, E. (1998). Nortriptyline and 1156
 1156 cognitive-behavioral therapy in the treatment of cigarette 1157
 1157 smoking. *Archives of General Psychiatry*, 55, 683–690.
- 1158 Hall, S. M., Tsoh, J. Y., Prochaska, J. J., Eisendrath, S., Rossi, 1159
 1159 J. S., Redding, C. A., Rosen, A. B., Meisner, M., Humfleet, 1160
 1160 G. L., & Gorecki, J. A. (2006). Treatment for cigarette 1161
 1161 smoking among depressed mental health outpatients: A 1162
 1162 randomized clinical trial. *American Journal of Public 1163
 1163 Health*, 96, 1808–1814.

- Heatherton, T., Kozlowski, L., Frecker, R., & Fagerström, K. (1991). The Fagerström Test for Nicotine Dependence: A revision of the Fagerström Tolerance Questionnaire. *British Journal of Addiction*, 86, 1119–1127.
- Herzog, T. A., Lazev, A. B., Irvin, J. E., Juliano, L. M., Greenbaum, P. E., & Brandon, T. H. (2002). Testing for group membership effects during and after treatment: The example of group therapy for smoking cessation. *Behavior Therapy*, 33, 29–43.
- Hitsman, B., Borrelli, B., McChargue, D. E., Spring, B., & Niaura, R. (2003). History of depression and smoking cessation outcome: A meta-analysis. *Journal of Consulting and Clinical Psychology*, 71, 657–663.
- Jacobson, N. S., Dobson, K. S., Truax, P. A., Addis, M. E., Koerner, K., Gollan, J. K., Gortner, E., & Prince, S. E. (1996). A component analysis of cognitive-behavioral treatment for depression. *Journal of Consulting and Clinical Psychology*, 64, 295–304.
- Just, N., Abramson, L. Y., & Alloy, L. B. (2001). Remitted depression studies as tests of the cognitive vulnerability hypotheses of depression onset: A critique and conceptual analysis. *Clinical Psychology Review*, 21, 63–83.
- Kahler, C. W., Brown, R. A., Lloyd-Richardson, E. E., & Niaura, R. (2003). History of major depressive disorder among smokers in cessation treatment: Associations with dysfunctional attitudes and coping. *Addictive Behaviors*, 28, 1033–1047.
- Kassel, J. D., Stroud, L. R., & Paronis, C. A. (2003). Smoking, stress, and negative affect: Correlation, causation, and context across stages of smoking. *Psychological Bulletin*, 129, 270–304.
- Latimer, A. E., Katulak, N. A., Mowad, L., & Salovey, P. (2005). Motivating cancer prevention and early detection behaviors using psychologically tailored messages. *Journal of Health Communication*, 10, 137–155.
- Lewinsohn, P. M., Solomon, A., Seeley, J. R., & Zeiss, A. (2000). Clinical implications of “subthreshold” depressive symptoms. *Journal of Abnormal Psychology*, 109, 345–351.
- Marks, D. F., & Sykes, C. M. (2002). Randomized controlled trial of cognitive behavioural therapy for smokers living in a deprived area of London: Outcome at one-year follow-up. *Psychology Health & Medicine*, 7, 17–24.
- McGlinchey, J. B., Atkins, D. C., & Jacobson, N. S. (2002). Clinical significance methods: Which one to use and how useful are they? *Behavior Therapy*, 33, 529–550.
- Muller, D., Judd, C. M., & Yzerbyt, V. Y. (2005). When moderation is mediated and mediation is moderated. *Journal of Personality and Social Psychology*, 89, 852–863.
- Muñoz, R., Organista, K., & Hall, S. (1993). *Mood management training to prevent smoking relapse: A cognitive-behavioral treatment manual*. San Francisco: University of California, San Francisco.
- Niaura, R., Britt, D. M., Shadel, W. G., Goldstein, M., Abrams, D., & Brown, R. (2001). Symptoms of depression and survival experience among three samples of smokers trying to quit. *Psychology of Addictive Behaviors*, 15, 13–17.
- Noar, S. M., Benac, C. N., & Harris, M. S. (2007). Does tailoring matter? Meta-analytic review of tailored print health behavior change interventions. *Psychological Bulletin*, 133, 673–693.
- Patten, C. A., Drews, A. A., Myers, M. G., Martin, J. E., & Wolter, T. D. (2002). Effect of depressive symptoms on smoking abstinence and treatment adherence among smokers with a history of alcohol dependence. *Psychology of Addictive Behaviors*, 16, 135–142.
- Patten, C., Martin, J., Myers, M., Calfas, K., & Williams, C. (1998). Effectiveness of cognitive-behavioral therapy for smokers with histories of alcohol dependence and depression. *Journal of Studies on Alcohol*, 59, 327–335.
- Persons, J. B., Bostrom, A., & Bertagnoli, A. (1999). Results of randomized controlled trials of cognitive therapy for depression generalize to private practice. *Cognitive Therapy and Research*, 23, 535–548.
- Pomerleau, C., Carton, S., Lutzke, M., Flessland, K., & Pomerleau, O. (1994). Reliability of the Fagerström Tolerance Questionnaire and the Fagerström Test for Nicotine Dependence. *Addictive Behaviors*, 19, 33–39.
- Raab, G. M., Day, S., & Sales, J. (2000). How to select covariates to include in the analysis of a clinical trial. *Controlled Clinical Trials*, 21, 330–342.
- Rabois, D., & Haaga, D. A. F. (1997). Cognitive coping, history of depression, and cigarette smoking. *Addictive Behaviors*, 22, 789–796.
- Schloss, H. M., & Haaga, D. A. F. (in press). Interrelating behavioral measures of distress tolerance with self-reported experiential avoidance. *Journal of Rational-Emotive & Cognitive-Behavior Therapy*.
- Shiffman, S., Paty, J. A., Gnys, M., Kassel, J. A., & Hickcox, M. (1996). First lapses to smoking: Within-subjects analysis of real-time reports. *Journal of Consulting and Clinical Psychology*, 64, 366–379.
- Smith, S. S., Jorenby, D. E., Fiore, M. C., Anderson, J. E., Mielke, M. M., Beach, K. E., Piasecki, T. M., & Baker, T. B. (2001). Strike while the iron is hot: Can stepped-care treatments resurrect relapsing smokers? *Journal of Consulting and Clinical Psychology*, 69, 429–439.
- SRNT Subcommittee on Biochemical Verification. (2002). Biochemical verification of tobacco use and cessation. *Nicotine & Tobacco Research*, 4, 149–159.
- Strong, D. R., Brown, R. A., Kahler, C. W., Lloyd-Richardson, E. E., & Niaura, R. (2004). Depression proneness in treatment-seeking smokers: A taxometric analysis. *Personality and Individual Differences*, 36, 1155–1170.
- Thorndike, F. P., Friedman-Wheeler, D. G., & Haaga, D. A. F. (2006). Effect of cognitive behavior therapy on smokers' compensatory coping skills. *Addictive Behaviors*, 31, 1705–1710.
- United States Department of Health and Human Services. (2008, May). *Clinical Practice Guideline: Treating tobacco use and dependence: 2008 update*. Retrieved April 26, 2010, from <http://www.surgeongeneral.gov/tobacco/index.html>
- Ziedonis, D., Hitsman, B., Beckham, J. C., Zvolensky, M., Adler, L. E., Audrain-McGovern, J., Breslau, N., Brown, R. A., George, T. P., Williams, J., Calhoun, P. S., & Riley, W. T. (2008). Tobacco use and cessation in psychiatric disorders: National Institute of Mental Health report. *Nicotine & Tobacco Research*, 10(12), 1–25.

RECEIVED: June 18, 2009

ACCEPTED: October 22, 2009

Q2